Immune-Based Lymphoma Treatment Sho... ( Similar patient-tailored approaches m...)

Immune-Based Lymphoma Treatment Shows Promise

Date:5/31/2009

Similar patient-tailored approaches may work for skin, stomach and other cancers, researchers say

SUNDAY, May 31 (HealthDay News) -- In a new study, patients with follicular non-Hodgkin lymphoma who received a vaccine made from their own cancer cells went more than 44 months before relapsing, compared to only 30.6 months for those who didn't get the vaccine.

The vaccine trial was one of several studies from the new frontier of "personalized medicine" presented Sunday at the American Society of Clinical Oncology (ASCO) annual meeting, in Orlando, Fla.

The approach aims to hit cancer hard by tailoring treatments to the patient's own genetics or disease, among other factors.

The lymphoma study differs from other vaccine trials in that the tool was patient-specific, study author Dr. Stephen Schuster, an associate professor at the University of Pennsylvania School of Medicine, explained at a Sunday news conference.

The findings could signal a whole new direction in how vaccines are used against cancer, experts said.

"The novelty of the vaccines is that they were individualized to each patient, and that they were directed against a cancer-specific target," said Dr. Louis Weiner, director of Georgetown's Lombardi Comprehensive Cancer Center in Washington, D.C. "Many vaccines are directed against cancer-associated targets and always run the risk of damage to normal cells."

But the lymphoma vaccine is "almost like an immune-system 'smart bomb,'" Weiner noted. "It only goes after malignant cells, and that's very attractive."

For this phase III trial, 76 patients who had been in remission for at least six months following chemotherapy were injected with BiovaxID, a vaccine engineered from cancerous tissues drawn from each individual patient. The mixture also contained compounds designed to heighten the effect of the vaccine.

These individualized vaccines took about three mo
'/>"/>

1

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Immune-based drug approved in Europe for pediatric cancer patients
2. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
3. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
4. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
5. January 1 Looms Large for Lymphoma Patients
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. Possible Cure for Rare Lymphoma Reported
8. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
9. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
10. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
11. Lymphoma drug used to treat skin disorders

Post Your Comments:

Immune-Based Lymphoma Treatment Sho...( Similar patient-tailored approaches m...),Health